United Kingdom (UK)
Recombinant monoclonal antibody to Aspartate beta-hydroxylase. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma G3-F11.
UniProt Accession Number of Target Protein: Q12797
Alternative Name(s) of Target: HAAH; ASPH; BAH; ASP beta-hydroxylase; Aspartyl beta-hydroxylase; Aspartyl/asparaginyl beta-hydroxylase; Peptide-aspartate beta-dioxygenase; G3/F11; G3; F11
Immunogen: The original antibody was generated by immunizing mice with naked plasmid DNA containing N-terminal domain of encoding HAAH gene and recombinant HAAH polypeptide.
Specificity: This antibody recognizes and binds human aspartyl/asparaginyl beta-hydroxylase. The human aspartyl (asparaginyl) beta-hydroxylase (HAAH) is an a-ketoglutarate-dependent dioxygenase, which is a membrane-associated and highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins. Overexpression of HAAH is recognized as an indicator for carcinomas in humans.
Application Notes: The specificity and sensitivity of this antibody for human aspartyl (asparaginyl) beta-hydroxylase (HAAH) was determined using ELISA and western blot (PMID: 19663697). This antibody was also used in the identification of HAAH expression in seven tumor tissues, including hepatocellular carcinoma, lung cancer, kidney cancer, cholangiocarcinoma, prostate cancer, breast cancer, and glioblastoma by immunohistochemical stain (PMID: 19663697; 25394783).
Antibody first published in:
Xue et al. Monoclonal antibodies against human aspartyl (asparaginyl) beta-hydroxylase developed by DNA immunization. Hybridoma (Larchmt). 2009 Aug;28(4):251-7. PMID:19663697
Note on publication:
Describes the generation of antibodies against human aspartyl (asparaginyl) beta-hydroxylase using DNA immunization.